ABS-201: A New Hope for Androgenic Alopecia
ABS-201 emerges as a potential best-in-class anti-PRLR antibody targeting androgenic alopecia, a condition affecting approximately 80 million individuals in the U.S. alone. With a preclinical profile indicating high affinity, potency, favorable safety, and extended half-life, ABS-201 promises a safer alternative to current treatments. Preclinical models have shown improved hair regrowth compared to minoxidil, with a Phase 1 clinical trial anticipated to begin in the first half of 2026.
ABS-101: Targeting TL1A with Reduced Immunogenicity
ABS-101, an anti-TL1A antibody, demonstrates high affinity and potency, with the ability to bind both monomer and trimer forms of TL1A. It shows potential for subcutaneous administration every 8-12 weeks, with preliminary data suggesting a lower chance of developing anti-drug antibodies compared to competitors. A Phase 1 clinical trial is expected to start in the first half of 2025.
ABS-301: A Novel Approach to Immuno-Oncology
Discovered through Absci’s AI Reverse Immunology platform, ABS-301 targets an undisclosed immuno-oncology marker with potential applications in squamous cell carcinomas and beyond. With high affinity and potency, Absci anticipates selecting a drug candidate by the first half of 2025.
ABS-501: Revolutionizing HER2 Treatment
ABS-501, an AI-designed anti-HER2 antibody, showcases novel epitope interactions and efficacy against trastuzumab-resistant tumors. With good developability and multiple therapeutic development paths under consideration, a drug candidate selection is expected by 2025.
AI Platform Breakthrough: A Step Towards a Universal HIV Vaccine
In collaboration with the California Institute of Technology, Absci has achieved a breakthrough by designing antibodies targeting a challenging epitope in the HIV 'caldera' region. This advancement could pave the way for a universal HIV vaccine, demonstrating the capability of AbsciDesign to target previously inaccessible conserved epitopes.
Absci's 2024 R&D Day highlighted the company's commitment to leveraging AI and scalable wet lab technologies to accelerate drug development and improve therapeutic outcomes. For more information, visit Absci's investor relations website.
